Alterity Therapeutics receives UK MHRA nod to proceed phase 2 trial of ATH434 to treat multiple system atrophy
By, Admin1 min read
Share
Alterity Therapeutics, a clinical stage biotechnology company, announced that the United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA) has accepted Alterity
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
